Rosenson Robert S
Preventive Cardiology Center, Northwestern University, Chicago, IL, USA.
Am Heart J. 2006 Mar;151(3):556-63. doi: 10.1016/j.ahj.2005.03.049.
A low level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for cardiovascular disease; however, patients with low levels of HDL-C without raised low-density lipoprotein cholesterol (LDL-C) levels are not currently eligible for lipid-lowering therapy. Many individuals with low levels of HDL-C have a combination of cardiovascular risk factors that include high LDL particle concentrations. Lowering LDL particle concentration and its surrogate measure, LDL-C, is an important approach to reducing cardiovascular risk. Statins are the most effective agents for lowering levels of LDL and can significantly increase levels of HDL-C. Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients.
高密度脂蛋白胆固醇（HDL-C）水平低是心血管疾病的主要危险因素；然而，目前HDL-C水平低但低密度脂蛋白胆固醇（LDL-C）水平未升高的患者不符合降脂治疗的条件。许多HDL-C水平低的个体存在包括高LDL颗粒浓度在内的多种心血管危险因素。降低LDL颗粒浓度及其替代指标LDL-C是降低心血管风险的重要方法。他汀类药物是降低LDL水平最有效的药物，并且可以显著提高HDL-C水平。将他汀类药物治疗扩展至HDL-C水平低但LDL-C水平低于目标值的患者，可能对降低这些患者的心血管疾病风险有益。
